Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Topiglan MacroChem.

Chris G McMahon¹

¹Australian Center for Sexual Health, St Luke's Hospital Complex, Sydney. cmcmahon@mail.usyd.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)

|July 2, 2002

Summary

Topiglan, a topical gel for erectile dysfunction, utilizes prostaglandin E1 (PGE1) and SEPA technology for enhanced skin absorption. Clinical trials and patent filings indicate its development progress toward a potential market launch.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Unfinished Business of Defining Premature Ejaculation: The Need for Targeted Research.

Sexual medicine reviews·2022

Same author

Disorders of Ejaculation: An AUA/SMSNA Guideline.

The Journal of urology·2021

Same author

Advances and Missteps in Diagnosing Premature Ejaculation: Analysis and Future Directions.

The journal of sexual medicine·2021

Same author

Response to Letter to the Editor Regarding "Cligosiban for Premature Ejaculation: Success, Failure, or Insufficiently Tested?"

The journal of sexual medicine·2019

Same author

Pharmacokinetics, Clinical Efficacy, Safety Profile, and Patient-Reported Outcomes in Patients Receiving Subcutaneous Testosterone Pellets 900 mg for Treatment of Symptoms Associated With Androgen Deficiency.

The journal of sexual medicine·2017

Same author

Changes in the Effects of Peyronie's Disease After Treatment With Collagenase Clostridium histolyticum: Male Patients and Their Female Partners.

Sexual medicine·2017

Area of Science:

Pharmacology
Dermatology
Drug Delivery Systems

Background:

Erectile dysfunction (ED) is a significant health concern requiring effective treatment options.
Transdermal drug delivery offers a promising route for therapeutic agent administration.
Prostaglandin E1 (PGE1, alprostadil) has shown potential in treating ED.

Purpose of the Study:

To evaluate the efficacy and safety of Topiglan, a novel topical gel for erectile dysfunction.
To assess the performance of the patented SEPA (Skin Excipient Permeation) technology in enhancing transdermal absorption of PGE1.
To document the regulatory and patent landscape surrounding Topiglan development.

Main Methods:

Topiglan, a topical gel formulation containing prostaglandin E1 (PGE1) and SEPA technology, was developed.
Phase III clinical trials were conducted to assess the treatment's efficacy and safety.
Preclinical studies investigated the safety profile of the SEPA excipient.
Patent applications were filed globally to protect the intellectual property.

Main Results:

Topiglan is in Phase III clinical trials for erectile dysfunction treatment.
The patented SEPA technology enhances the transdermal absorption of therapeutic agents.
SEPA excipient demonstrated no tumor development in rats.
US patent granted in August 1999, with further applications pending internationally.

Conclusions:

Topiglan, utilizing PGE1 and SEPA technology, shows potential for treating erectile dysfunction.
The SEPA technology is a key innovation for transdermal drug delivery.
MacroChem is actively pursuing regulatory approval and global patent protection for Topiglan.

Related Experiment Videos